Clinical Trial Update: Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study [Phase 3]

View source ↗

Summary

A Phase 3 bridging study evaluating tanezumab given subcutaneously versus intravenous in osteoarthritis shows terminated status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis
• Osteoarthritis

Drugs mentioned

• Tanezumab (tanezumab)

Snippet

Sponsor: Pfizer | Conditions: Osteoarthritis, Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2021-05-05